Wight, JoelHamad, NadaCampbell, Belinda A.Ku, MatthewLee, KennethRose, HannahArmytage, TasmanLatimer, MayaLee, Hui PengLee, Sze TingDickinson, MichaelKhor, RichardVerner, Emma2025-03-142025-03-14researchoutputwizard:a383154xPUB35990Scopus:85134505013https://dspace-test.anu.edu.au/handle/1885/733715655Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30–40% of lymphoma diagnoses. Although aggressive, cure is achievable in approximately 60% of cases with primary chemoimmunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, central nervous system prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.Conflict of interest: J. Wight: honoraria and travel support from Janssen, Abbvie; advisory board for Alexion. E. Verner: research funding from Janssen. M. Dickinson: advisory boards: Roche, Novartis, MSD, Janssen, BMS, Gilead, Kite; research support: Roche, Novartis, MSD, Takeda, BMS, Celgene, Gilead. R. Khor: honoraria and travel expenses from Elekta.EnglishPublisher Copyright: © 2021 Royal Australasian College of Physicians.diagnosisdiffuse large B-cell lymphomamanagementprognosis202110.1111/imj.15533http://www.scopus.com/inward/record.url?scp=85134505013&partnerID=8YFLogxK